At its July meeting, the Pharmaceutical Benefits Advisory Committee will consider new therapies for Alzheimer's disease, ovarian cancer, and cystic fibrosis, and a range of biosimilars, generics and new forms of already listed medicines. …
Anticipated therapies and not-so-anticipated dominate July PBAC agenda
April 2, 2025 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 26 September
September 26, 2025 - - Podcast -
Waiting for any impact. Why the Albanese Government will hold fire on 'MFN'
September 26, 2025 - - Latest News -
Boehringer Ingelheim pushes for patient voices to lead policy reform
September 26, 2025 - - Latest News -
TGA consulting on the ongoing need for paper product information inserts
September 25, 2025 - - Latest News -
Gene therapy shows early promise in slowing Huntington’s Disease
September 25, 2025 - - Australian Biotech -
Federal minister to address AusBiotech International Conference as sector marks critical juncture
September 25, 2025 - - Australian Biotech -
Recce Pharmaceuticals begins patient dosing in pivotal diabetic foot infection trial
September 25, 2025 - - Australian Biotech